OGDH
2-oxoglutarate dehydrogenase complex component E1
Also known as: E1k, KGD1, ODO1_HUMAN, OGDC-E1, OGDH2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q02218
- Gene
- OGDH
- Ensembl
- ENSG00000105953
- Chromosome
- 7
- Canonical length
- 1023 aa
- Protein class
- Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Mitochondria
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes one subunit of the 2-oxoglutarate dehydrogenase complex. This complex catalyzes the overall conversion of 2-oxoglutarate (alpha-ketoglutarate) to succinyl-CoA and CO(2) during the Krebs cycle. The protein is located in the mitochondrial matrix and uses thiamine pyrophosphate as a cofactor. A congenital deficiency in 2-oxoglutarate dehydrogenase activity is believed to lead to hypotonia, metabolic acidosis, and hyperlactatemia. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Sep 2009]
Canonical amino-acid sequenceUniProt
1023 residues, UniProt reviewed canonical sequence.
>Q02218|OGDH
1 MFHLRTCAAK LRPLTASQTV KTFSQNRPAA ARTFQQIRCY SAPVAAEPFL SGTSSNYVEE
61 MYCAWLENPK SVHKSWDIFF RNTNAGAPPG TAYQSPLPLS RGSLAAVAHA QSLVEAQPNV
121 DKLVEDHLAV QSLIRAYQIR GHHVAQLDPL GILDADLDSS VPADIISSTD KLGFYGLDES
181 DLDKVFHLPT TTFIGGQESA LPLREIIRRL EMAYCQHIGV EFMFINDLEQ CQWIRQKFET
241 PGIMQFTNEE KRTLLARLVR STRFEEFLQR KWSSEKRFGL EGCEVLIPAL KTIIDKSSEN
301 GVDYVIMGMP HRGRLNVLAN VIRKELEQIF CQFDSKLEAA DEGSGDVKYH LGMYHRRINR
361 VTDRNITLSL VANPSHLEAA DPVVMGKTKA EQFYCGDTEG KKVMSILLHG DAAFAGQGIV
421 YETFHLSDLP SYTTHGTVHV VVNNQIGFTT DPRMARSSPY PTDVARVVNA PIFHVNSDDP
481 EAVMYVCKVA AEWRSTFHKD VVVDLVCYRR NGHNEMDEPM FTQPLMYKQI RKQKPVLQKY
541 AELLVSQGVV NQPEYEEEIS KYDKICEEAF ARSKDEKILH IKHWLDSPWP GFFTLDGQPR
601 SMSCPSTGLT EDILTHIGNV ASSVPVENFT IHGGLSRILK TRGEMVKNRT VDWALAEYMA
661 FGSLLKEGIH IRLSGQDVER GTFSHRHHVL HDQNVDKRTC IPMNHLWPNQ APYTVCNSSL
721 SEYGVLGFEL GFAMASPNAL VLWEAQFGDF HNTAQCIIDQ FICPGQAKWV RQNGIVLLLP
781 HGMEGMGPEH SSARPERFLQ MCNDDPDVLP DLKEANFDIN QLYDCNWVVV NCSTPGNFFH
841 VLRRQILLPF RKPLIIFTPK SLLRHPEARS SFDEMLPGTH FQRVIPEDGP AAQNPENVKR
901 LLFCTGKVYY DLTRERKARD MVGQVAITRI EQLSPFPFDL LLKEVQKYPN AELAWCQEEH
961 KNQGYYDYVK PRLRTTISRA KPVWYAGRDP AAAPATGNKK THLTELQRLL DTAFDLDVFK
1021 NFSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against OGDH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 350 nTPM
Expression across tissuesHPA
Tissue
- tongue: 350 nTPM
- skeletal muscle: 341 nTPM
- heart muscle: 302 nTPM
- choroid plexus: 105 nTPM
- parathyroid gland: 94 nTPM
- duodenum: 90 nTPM
Single-cell type
- choroid plexus epithelial cells: 399 nCPM
- neutrophils: 394 nCPM
- myonuclei: 365 nCPM
- enterocytes: 331 nCPM
- monocytes: 284 nCPM
- distal convoluted tubule cells: 266 nCPM
Immune cell
- T-reg: 42 nTPM
- non-classical monocyte: 36 nTPM
- intermediate monocyte: 28 nTPM
- total PBMC: 23 nTPM
- myeloid DC: 22 nTPM
- classical monocyte: 22 nTPM
Brain region
- choroid plexus: 259 nTPM
- hypothalamus: 113 nTPM
- midbrain: 101 nTPM
- thalamus: 99 nTPM
- medulla oblongata: 98 nTPM
- cerebral cortex: 98 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about OGDH.
Disease | GeneticClinVar
5 pathogenic / likely-pathogenic of 278 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Oxoglutaricaciduria
Disease | ImmuneIEDB
Conditions an epitope on OGDH was assayed in.
- Parkinson's disease T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.27
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.76
- DepMap mean gene effect
- -0.59
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 2-oxoglutarate decarboxylation to succinyl-CoA
- 2-oxoglutarate metabolic process
- cerebellar cortex development
- generation of precursor metabolites and energy
- glycolytic process
- hippocampus development
- olfactory bulb mitral cell layer development
- pyramidal neuron development
- striatum development
- succinyl-CoA metabolic process
- tangential migration from the subventricular zone to the olfactory bulb
- thalamus development
- tricarboxylic acid cycle
Molecular functions
- heat shock protein binding
- metal ion binding
- oxoglutarate dehydrogenase (succinyl-transferring) activity
- protein-folding chaperone binding
- thiamine pyrophosphate binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Dehydrogenase, E1 component
- Transketolase-like, pyrimidine-binding domain
- 2-oxoglutarate dehydrogenase E1 component
- Thiamin diphosphate-binding fold
- 2-oxoglutarate dehydrogenase E1 component/KDG, C-terminal
- 2-oxoglutarate dehydrogenase E1 component, N-terminal domain
- Multifunctional 2-oxoglutarate metabolism enzyme, C-terminal domain superfamily
- Dehydrogenase E1 component
- Transketolase, pyrimidine binding domain
- 2-oxoglutarate dehydrogenase N-terminus
- 2-oxoglutarate dehydrogenase C-terminal
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of OGDH in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads OGDH as an antibody target. Whether an autoantibody or antibody against OGDH could matter depends on whether native OGDH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
OGDH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label OGDH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...